RFK Jr. it puts the FDA team and peptide suppliers as FDA scientists challenge the opportunity

Although the FDA is not required to accept recommendations from its advisory committees, it often does. In the first draft of the meeting next month, the commission said it “does not intend to make a final decision on the current issue until the recommendations of the advisory committee have been considered and all comments have been completed. The final decision may be affected by matters not discussed at the advisory meeting.”

New and old members

The nine new members are:

Gabriel Alizaidy, who promotes peptides on social media and in the newsletters he runs. He is the director of science at Maximusa “functional medicine” clinic that offers peptide injections. The FDA recently sent a warning letter to Maximus on “false or misleading” statement on peptides used for weight loss, The Washington Post reported.

Asare B. Christian, a medical doctor who founded it Medicine of the Aether in Pennsylvania, which uses peptides to treat pain, anti-aging, trauma, and neurological disorders.

Robert Harshbarger, a Republican senator from Tennessee who is a pharmacist and the son of Rep. Diana Harshbarger (R). In November, Diana Harshbarger in particular asked Kennedy to have the FDA review the six peptides.

Melissa Loseke, founder and clinical director Re-New Institute in Nebraska, which offers peptide therapy with a focus on “whole person healing” and a mission to “enhance life.”

Haleem Mohammed is a senior physician at Gameday Men’s Healthwhich offers peptide therapy as part of “hormonal optimization, vitality and longevity care.”

Gerald Morris, medical director of Wellness Clinic AMG Medical in Tucson, Arizona. His website says he is “interested in therapeutics, peptide therapy, and human longevity.

Josh Starbuck, concierge doctor in Hawaii that focuses on functional medicine and peptide therapy for anti-aging and longevity.

Kris Wusterhausen, founder of The Resurge Clinichealth and longevity clinic in Texas, which promotes peptides.

The last one is David Pope, a the head of the pharmacy at XiFin Pharmacy Solution, a company that develops medical services and payment software. It is unclear whether he has a public opinion on the use of the peptide.

The four previous members are:

Timothy Fensky, a pharmaceutical industry consultant and representative from the National Association of Boards of Pharmacy.

Elizabeth Rebello, an anesthesiologist and executive director of the University of Texas MD Anderson Cancer Center.

Brian Serumaga, director of personalized medicine at the US Pharmacopeia.

Donnette Staas, vice president of regulatory affairs at Jazz Pharmaceuticals, is a non-voting company representative.